MCU will be able to fund the Phase III MEND-CABG II study through to completion without a partnership but that should be the last option.
A partnership is absolutly necessary to start their phase 3 trials in MC-4232 and MC-1 for ACS. Does Medicure want to wait further 18-20 months with the advancement of these programs? I think not, that´s not acceptable!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.